Itareparib clinical trials
Also written NMS-03305293.
How each study uses itareparib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the itareparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NMS-03305293
- 4
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Nerviano Medical Sciences (4)
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test itareparib.
- May 2027Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaPhase 1/2 · Nerviano Medical Sciences
Studies
Open first, then newest update. How each study uses itareparib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung CancerRecruitingPhase 1Nerviano Medical SciencesNCT06931626Written as NMS-03305293
- Study of NMS-03305293 in Adult Patients With Relapsed Ovarian CancerTerminatedPhase 1Nerviano Medical SciencesNCT06930755Written as NMS-03305293
- Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaActive, not recruitingPhase 1/2Nerviano Medical SciencesNCT04910022Written as NMS-03305293
- Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid TumorsTerminatedPhase 1Nerviano Medical SciencesNCT04182516Written as NMS-03305293
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- Study of NMS-03305293 in Adult Patients With Relapsed Ovarian CancerTerminatedNov 16, 2026NCT06930755
Codes
What other systems call itareparib · ClinicalTrials.gg INT017065
- UNII (FDA) KFI1190L8LITAREPARIBOne source FDA
- NCI Thesaurus C215740ItareparibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KFI1190L8L | ITAREPARIB | One source FDA |
| NCI Thesaurus | C215740 | Itareparib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.